innerbuddies gut microbiome testing

Gut Microbiome in Established Type 1 Diabetes: How Microbes May Influence Blood Sugar

In established type 1 diabetes (T1D), blood sugar regulation depends on insulin, but growing evidence suggests the gut microbiome can also shape metabolic control. Your trillions of intestinal microbes influence how your body processes nutrients, communicates with the immune system, and produces metabolites that may affect glucose availability and insulin sensitivity—even after autoimmunity has already started.

Researchers have found that T1D is often associated with an altered gut microbial balance, sometimes described as reduced diversity and shifts in the abundance of specific bacterial groups. These changes can influence gut barrier integrity and immune signaling, potentially increasing low-grade inflammation. Inflammation, in turn, can worsen glycemic stability by affecting insulin action and altering how the body responds to dietary carbohydrates.

Importantly, the microbiome doesn’t just “mirror” diabetes—it may actively contribute to the environment your immune system and metabolism experience. Microbial metabolites such as short-chain fatty acids (SCFAs) and other fermentation byproducts can modulate inflammation and metabolic pathways, while microbial byproducts may also affect gut permeability and immune activation. Understanding these gut–immune–metabolic links could help explain variability in glucose control in established T1D and guide future microbiome-focused interventions.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Established T1D

Established T1D is driven by insulin deficiency, but the gut microbiome also helps shape day-to-day glucose control. Studies show altered microbial diversity and metabolic function in people with T1D, linked to inflammation and changes in circulating metabolites related to glycemic regulation. Dysbiosis may contribute to glycemic instability by weakening gut-barrier integrity and increasing exposure to immune signals.

Microbial metabolites and signaling pathways influence glucose homeostasis beyond inflammation, including effects on incretin hormones like GLP-1 and bile-acid signaling that regulate hepatic glucose output. Short-chain fatty acids such as butyrate and other fermentation products can modulate immune tone and nutrient handling, potentially driving swings between hyper- and hypoglycemia. Altered gut-barrier function also promotes chronic low-grade inflammation that can further impair insulin sensitivity.

Microbiome testing can reveal patterns linked to barrier health, metabolite production, and inflammatory potential, helping explain persistent glucose swings even with optimized insulin therapy. Such insights can guide personalized diet and therapeutic adjustments to reduce inflammatory pressure and stabilize glycemia. Programs like InnerBuddies aim to translate microbiome signatures into actionable dietary and care strategies for established T1D.

  • In established T1D, gut dysbiosis with reduced diversity and loss of butyrate-producing taxa (Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Anaerostipes, Bifidobacterium spp.) lowers SCFA production, promoting inflammation and day-to-day glycemic instability.
  • An expansion of pro-inflammatory taxa (Escherichia/Shigella, Enterobacteriaceae, Ruminococcus gnavus group, Collinsella, Streptococcus, Enterococcus) is linked to gut barrier disruption and higher systemic inflammation, worsening insulin sensitivity and glucose swings.
  • Dysbiosis-driven gut-barrier dysfunction increases intestinal permeability, allowing immune triggers to heighten chronic inflammation and impair peripheral insulin signaling.
  • Microbial metabolites like butyrate and bile-acid derivatives modulate incretin signaling (e.g., GLP-1) and FXR/TGR5 pathways, influencing hepatic glucose output and intestinal nutrient handling to affect hyperglycemia/hypoglycemia in established T1D.
  • Altered bile-acid metabolism and carbohydrate fermentation by the microbiome shift circulating metabolites, impacting glycemic control and energy balance in established T1D.
  • Targeted microbiome-modulating strategies (diet, prebiotics/probiotics, or future therapies) aiming to restore beneficial taxa (A. muciniphila, F. prausnitzii, Roseburia, E. rectale, Anaerostipes, Bifidobacterium) and tamp down harmful taxa (Escherichia/Shigella, Enterobacteriaceae, Ruminococcus gnavus) may improve glycemic stability and GI tolerance.
Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Type 1 diabetes (T1D)

In established type 1 diabetes (T1D), the immune system’s attack on pancreatic beta cells leads to chronic insulin deficiency, but blood-sugar control is influenced by more than insulin alone. Growing evidence suggests that the gut microbiome—communities of bacteria, archaea, and other microbes living in the intestine—can affect glucose metabolism, inflammation, and how the body responds to food and insulin. In people with established T1D, studies have reported differences in gut microbial composition and diversity compared with those without the condition, alongside functional changes in microbial metabolic pathways that can shape circulating metabolites relevant to glycemic control.

One key hypothesis is that gut microbial imbalance (dysbiosis) may modulate inflammation, a major driver of metabolic instability even after diagnosis. Certain microbial patterns can influence the gut barrier (tight junction integrity and permeability), alter exposure to immune-activating signals, and affect levels of inflammatory mediators. This matters for established T1D because systemic inflammation can worsen insulin sensitivity and contribute to more variable glucose levels. Microbes also produce metabolites—such as short-chain fatty acids (e.g., butyrate), bile acid derivatives, and other fermentation products—that can interact with host signaling pathways involved in glucose regulation, immune tone, and energy balance.

Researchers are also investigating how the microbiome might influence insulin dynamics and metabolic control through pathways that go beyond inflammation. These include effects on gut-derived hormones (like GLP-1 and other incretin-related signals), alterations in bile acid metabolism that can regulate glucose homeostasis via receptors, and impacts on carbohydrate fermentation and intestinal nutrient handling. While findings are not yet uniform and causality remains an active area of study, the overall direction of research supports the idea that targeting the gut microbiome—through diet quality, prebiotics/probiotics, or future microbiota-based therapies—could help improve metabolic outcomes and complement standard diabetes care in established T1D.

  • Fluctuating blood glucose levels (hyperglycemia and hypoglycemia swings)
  • Increased frequency of urination (polyuria)
  • Excessive thirst (polydipsia)
  • Unexplained weight loss or difficulty maintaining weight
  • Fatigue and low energy
  • Increased susceptibility to infections due to impaired immune balance
  • GI disturbances (bloating, diarrhea, constipation) that may reflect dysbiosis
Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Established T1D

This information is most relevant for people living with established type 1 diabetes (T1D) who are trying to understand why blood-glucose patterns can fluctuate despite taking insulin. If you notice frequent swings between hyperglycemia and hypoglycemia, you may be interested in research showing that the gut microbiome can influence glucose metabolism and inflammatory signaling—two factors that may worsen metabolic stability even after diagnosis.

It may also be especially relevant for individuals experiencing ongoing “system-level” symptoms that suggest more than insulin deficiency alone, such as increased thirst and urination (polyuria/polydipsia), unexplained weight changes, persistent fatigue, or a higher tendency to infections. Emerging microbiome evidence links gut microbial imbalance to immune activation and gut-barrier function, which can contribute to systemic inflammation and thereby affect insulin sensitivity and day-to-day glycemic variability.

Finally, this topic is relevant for those with gastrointestinal disturbances (bloating, diarrhea, constipation) or ongoing digestive discomfort alongside their diabetes. Research focuses on how gut microbes produce metabolites—like short-chain fatty acids and bile acid derivatives—that interact with host pathways involved in glucose control, immune tone, and gut hormone signaling. If you’re curious about potential complementary approaches such as diet quality, prebiotics/probiotics, or future microbiome-based therapies, this overview helps contextualize why gut health may matter in established T1D.

Type 1 diabetes (T1D) is an uncommon but well-established condition worldwide, typically affecting children and young adults, with a lifetime prevalence that is generally reported in the range of about 0.5–2% across countries. Because the indication specifically describes established T1D, the relevant “prevalence” is best understood as the proportion of people living with diagnosed T1D rather than newly diagnosed cases. Globally, there are roughly 8–9 million people living with T1D, and estimates suggest around 1.2–1.3 million new diagnoses each year—meaning the number of people with established disease increases over time as survival improves.

Regarding gut-related features, there is no single percentage that quantifies “microbiome dysbiosis” in everyone with established T1D, because gut microbial composition is influenced by diet, medications (including metformin in some patients, antibiotics, and insulin delivery methods), geography, and study methods. However, multiple studies comparing people with T1D versus non-diabetic controls consistently report differences in gut microbiome diversity and taxonomic composition, alongside functional shifts in microbial metabolic pathways related to inflammation and metabolite production. In practical terms, this aligns with the common symptom cluster described—such as GI disturbances (bloating, diarrhea, constipation) that may reflect dysbiosis and contribute to metabolic instability—though the exact prevalence of GI symptoms varies widely between studies.

For symptom prevalence, hyperglycemia/hypoglycemia swings are common in established T1D due to insulin deficiency combined with factors beyond insulin alone (including inflammation and gut-derived signals). Polydipsia and polyuria are classic manifestations of inadequate insulin coverage or glucose variability, and their frequency depends on day-to-day glycemic control. Weight loss, fatigue, and increased infection susceptibility are also well recognized in T1D, particularly when glucose is poorly controlled; similarly, GI symptoms occur in a meaningful subset of people and may correlate with alterations in gut barrier function and microbiome-driven inflammation. Overall, while the gut microbiome component is highly prevalent at the microbial-pattern level (differences vs. controls), the prevalence of each GI symptom and the degree of dysbiosis differ across individuals with established T1D.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome in Established Type 1 Diabetes: How Microbes May Influence Blood Sugar

In established type 1 diabetes (T1D), insulin deficiency is central, but glucose control is also shaped by the gut microbiome. Research shows that people living with T1D often have differences in gut microbial diversity and community composition compared with people without T1D. Along with these shifts, microbial metabolic functions—such as carbohydrate fermentation and metabolite production—may change circulating compounds that influence glycemic stability, inflammation, and how the body responds to food.

A major connection is inflammation and gut-barrier health. Certain gut microbial patterns may affect intestinal permeability and tight-junction integrity, increasing exposure to immune-activating signals. Because chronic low-grade inflammation can worsen insulin sensitivity and contribute to glucose variability, microbiome-driven changes in immune signaling can help explain why established T1D may feature frequent blood-sugar swings and persistent metabolic instability even when insulin therapy is optimized.

The gut microbiome can also influence glucose regulation through microbial metabolites and signaling pathways beyond inflammation. Microbes produce short-chain fatty acids (including butyrate), modulate bile acid metabolism, and generate other fermentation products that interact with host metabolic and immune pathways. These gut-derived signals can affect incretin-related hormones (e.g., GLP-1), bile acid receptor signaling, and intestinal handling of nutrients—mechanisms that may contribute to symptoms such as fluctuating hyperglycemia/hypoglycemia, GI disturbances, and immune imbalance that can increase infection susceptibility.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Established T1D

  • Altered gut microbial diversity and dysbiosis in established T1D can shift carbohydrate fermentation and metabolite production, influencing circulating substrates involved in glycemic stability and variability.
  • Gut-barrier dysfunction and increased intestinal permeability (weakened tight junctions) can enhance translocation of microbial products (e.g., LPS), driving chronic low-grade inflammation that worsens metabolic control and contributes to blood-sugar swings.
  • Microbiome-driven immune modulation (changes in innate/adaptive immune signaling, T-cell balance, and cytokine tone) can sustain inflammatory pathways that impair insulin sensitivity and increase metabolic instability.
  • Short-chain fatty acid (SCFA) signaling—especially butyrate—can modulate glucose regulation through effects on gut hormone secretion (including incretin pathways), inflammation, and hepatic/muscle insulin responsiveness.
  • Bile acid metabolism and signaling changes (microbial conversion of primary to secondary bile acids and altered FXR/TGR5 signaling) can influence insulin dynamics, hepatic glucose output, and intestinal glucose absorption.
  • Microbial metabolite–host signaling (e.g., fermentation byproducts such as lactate/other SCFAs, tryptophan-derived metabolites) can affect glucose handling, appetite/food intake cues, and immune tone that indirectly impact glycemic control.
  • Incretin and nutrient-sensing pathway effects via microbial regulation of intestinal physiology can alter GLP-1/GIP release and gastric/intestinal nutrient processing, contributing to post-meal glycemic excursions.
  • Changes in microbial community function may increase or decrease susceptibility to GI disturbance and infection, which can destabilize glycemia through stress hormones, inflammation, and altered absorption.

In established type 1 diabetes (T1D), insulin deficiency is the primary driver of hyperglycemia, but gut microbial ecology also shapes how stable (or variable) glucose control feels day to day. Many people with established T1D show altered gut diversity and dysbiosis, which can shift carbohydrate fermentation and the types/amounts of microbial metabolites reaching the circulation. Those functional changes can influence circulating nutrients and byproducts that affect glycemic stability, metabolic flexibility, and inflammatory tone—helping explain why glucose swings may persist even when insulin therapy is carefully optimized.

A key mechanism involves gut-barrier dysfunction and low-grade inflammation. Dysbiosis can weaken intestinal tight junctions and increase permeability, allowing microbial components (such as LPS and other immunostimulatory signals) to cross into the host environment. This promotes chronic immune activation and cytokine-driven signaling that can impair insulin sensitivity in peripheral tissues and amplify metabolic instability. Over time, the resulting immune and inflammatory milieu can contribute to more frequent hyperglycemic/hypoglycemic excursions and worsened glycemic variability.

Beyond inflammation, microbial metabolites and nutrient-sensing pathways can directly modulate glucose regulation. Short-chain fatty acids (especially butyrate) can signal through metabolic and immune pathways, influencing incretin-related hormone dynamics (e.g., GLP-1), hepatic and muscle insulin responsiveness, and gut hormone release. Meanwhile, altered bile acid metabolism from gut microbes can change FXR/TGR5 signaling, affecting hepatic glucose output and intestinal glucose handling. Additional gut-derived signals—such as fermentation byproducts and tryptophan-related metabolites—can further influence gut physiology, appetite/food intake cues, immune balance, and susceptibility to gastrointestinal disturbance or infection, which can destabilize glycemia through stress hormones and inflammation.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In established type 1 diabetes (T1D), gut microbial ecology often shifts away from the patterns seen in people without the condition, with reduced overall diversity and changes in community composition. These taxonomic differences are not just “who is present,” but also reflect altered community function—how the microbiome processes dietary carbohydrates, proteins, and bile acids—leading to a distinct metabolic output that can affect day-to-day glucose stability. Such dysbiosis can also align with a higher inflammatory tone, which may help explain why glucose swings can persist even when insulin therapy is well optimized.

A core microbial pattern linked to established T1D involves effects on gut-barrier integrity and immune activation. Certain microbial communities and their functional products can influence tight-junction proteins and mucosal defenses, increasing intestinal permeability (“leaky gut”). When barrier function is compromised, immunostimulatory microbial components (for example, lipopolysaccharide and other pro-inflammatory molecules) are more likely to reach the host immune system, promoting chronic low-grade inflammation. This immune signaling can impair insulin sensitivity in peripheral tissues and amplify metabolic instability, contributing to greater variability in hyperglycemia and hypoglycemia.

Beyond inflammation, the functional metabolic profile of the gut microbiome is a major contributor to glycemic regulation. Altered carbohydrate fermentation can change circulating short-chain fatty acids (including butyrate), which act as signaling molecules through metabolic and immune pathways and can modulate incretin dynamics such as GLP-1. In parallel, changes in microbial bile-acid metabolism can reshape FXR/TGR5-related signaling that influences hepatic glucose production and intestinal nutrient handling. Together with additional microbial metabolites (including tryptophan-derived and fermentation byproducts), these gut-derived signals can affect gut physiology, stress/inflammatory responses, and susceptibility to gastrointestinal disturbances—factors that can further destabilize glycemia over time.


Low beneficial taxa

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Anaerostipes spp.
  • Bifidobacterium spp.
  • Bacteroides fragilis group (e.g., Bacteroides fragilis)
  • Clostridium cluster IV (butyrate-producing taxa)


Elevated / overrepresented taxa

  • Escherichia/Shigella
  • Bacteroides fragilis (less beneficial / inflammatory B. fragilis strains)
  • Proteobacteria (family/order-level elevation; e.g., Enterobacteriaceae)
  • Ruminococcus gnavus group
  • Collinsella
  • Streptococcus
  • Enterococcus


Functional pathways involved

  • Gut-barrier integrity and tight-junction modulation (mucus layer dynamics, epithelial permeability; SCFA/secondary-metabolite effects)
  • Innate immune activation via microbial components (LPS/TLR4 signaling and downstream NF-κB inflammatory tone)
  • Short-chain fatty acid (SCFA) fermentation—especially butyrate and acetate/propionate production pathways
  • Bile acid metabolism and signaling (primary-to-secondary conversion; FXR/TGR5 activation impacting hepatic glucose output and gut hormone release)
  • Incretin regulation through microbial metabolite signaling (GLP-1/GIP modulation via SCFAs and bile-acid–dependent effects)
  • Tryptophan-kynurenine and aryl hydrocarbon receptor (AhR) signaling (immune regulation and epithelial function)
  • Protein fermentation and branched-chain amino acid (BCAA) metabolism (inflammatory byproducts and metabolic crosstalk affecting insulin sensitivity)


Diversity note

In established type 1 diabetes (T1D), the gut microbiome commonly shows reduced overall microbial diversity compared with people without T1D. This shift often includes changes in the relative abundance of key bacterial groups and a broader restructuring of community composition, suggesting that the ecosystem is less resilient and more easily altered by diet, medications, and immune-metabolic stressors. Importantly, these differences in who is present are also typically accompanied by changes in what the community can do—its metabolic “output,” which can influence host glucose stability over time.

Beyond reduced diversity, dysbiosis in established T1D frequently reflects functional alterations in microbial processes that affect intestinal homeostasis. Microbial communities may contribute to weaker gut-barrier defenses and altered mucosal immune signaling, which can promote a chronic low-grade inflammatory tone. When diversity is lower and the community is less balanced, barrier-compromising effects and immunostimulatory signaling can become more prominent, potentially worsening metabolic instability and increasing susceptibility to gastrointestinal symptoms that can indirectly destabilize glycemia.

Functional changes tied to these compositional shifts often involve altered fermentation patterns and metabolite production, including short-chain fatty acids and other microbial-derived signaling compounds. Changes in how carbohydrates and bile acids are metabolized can reshape circulating and gut-local signaling pathways (such as those mediated by bile acid receptors and incretin-related effects). As a result, reduced diversity and altered microbial community function can work together to influence inflammatory signaling, nutrient handling, and metabolic responses to meals—factors that may help explain why glycemic swings can persist even with optimized insulin therapy.


Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic microbiome solutions often fail in established type 1 diabetes because T1D is not a single “dysbiosis” pattern; it is an interaction between an already established insulin-deficient state and gut ecology that may be altered in both composition and, critically, function. Many one-size-fits-all probiotics or broad-spectrum prebiotic blends assume similar baseline microbiota, dietary patterns, and immune tone across individuals. But in established T1D, reduced microbial diversity and community shifts can come with changes in how carbohydrates, proteins, and bile acids are metabolized—so the same supplement may not generate the intended metabolite output (e.g., short-chain fatty acids, bile-acid derivatives, or other fermentation signals) that influences glucose stability.

    A second reason generic approaches underperform is that they rarely target gut-barrier and immune activation mechanisms that can persist in established T1D. When barrier integrity is compromised, microbial components are more likely to trigger immune signaling and maintain a chronic low-grade inflammatory environment. That inflammation can worsen insulin sensitivity in peripheral tissues and amplify glycemic swings. Standard “good bacteria” strategies may not be sufficient to restore mucosal tight-junction function or shift immune-stimulatory signals without addressing upstream drivers such as diet-induced substrate availability, bile-acid signaling, fiber tolerance, dysregulated fermentation patterns, or medication-related effects on the gut ecosystem.

    Finally, glucose variability in established T1D is shaped by metabolite-mediated signaling pathways that generic interventions often miss. Microbial short-chain fatty acids (including butyrate), bile-acid metabolism affecting FXR/TGR5 signaling, and other gut-derived compounds influence incretin dynamics (such as GLP-1), hepatic glucose handling, and intestinal nutrient absorption. Generic products may not be aligned with an individual’s specific functional deficits—so even if the microbiome changes measurably, it may not translate into improved glycemic stability or symptom control. Without personalized matching of functional goals (barrier support, bile-acid pathway modulation, and metabolite production) to the patient’s gut function and tolerance, results tend to be inconsistent or short-lived.

  • Common mistakes

    • Using one-size-fits-all probiotics/prebiotics without accounting for established T1D’s person-specific gut composition and—more importantly—functional output (SCFAs, bile-acid derivatives, fermentation products).
    • Assuming “more bacteria diversity” automatically improves glucose stability, rather than targeting the functional deficits linked to immune tone, incretin signaling, and hepatic glucose handling.
    • Failing to address gut-barrier integrity and immune activation drivers (tight-junction dysfunction, microbial translocation/LPS signaling), which can persist despite generic microbial supplementation.
    • Ignoring dysregulated substrate availability and fermentation patterns (fiber type, carbohydrate handling, protein fermentation load), leading to minimal or misaligned metabolite production that affects glycemic variability.
    • Overlooking bile-acid metabolism pathways (FXR/TGR5 signaling) and using interventions that don’t match the patient’s bile-acid/microbiome functional state.
    • Not matching the intervention to individual tolerance and GI response, especially in established T1D where gut physiology may be more sensitive; this can cause adherence failure and worsening inflammation/fermentation.
    • Treating dysbiosis as the sole lever while neglecting medication-related and lifestyle contributors (e.g., diet composition, gut transit, antibiotic history), resulting in inconsistent outcomes.
    • Measuring microbiome changes superficially (taxa shifts) instead of verifying functional targets relevant to glucose stability (butyrate/SCFA profile, bile-acid signaling markers, inflammatory pathway activity).

What to do

  • General support strategies

    In established type 1 diabetes (T1D), insulin remains the primary treatment, but gut health and the gut microbiome can meaningfully influence glucose patterns through immune signaling, inflammation, and nutrient metabolism. Support strategies often focus on optimizing the intestinal environment—encouraging a more diverse, resilient microbial community and reducing factors that may promote gut-barrier dysfunction. Because chronic low-grade inflammation and increased intestinal permeability have been linked to poorer metabolic stability, approaches that support tight-junction integrity and lower pro-inflammatory signaling may help reduce glycemic variability and improve overall metabolic resilience.

    Diet is typically the cornerstone of gut-support for established T1D. Emphasizing high-fiber foods (especially prebiotic fibers and minimally processed carbohydrates that microbes can ferment) supports beneficial fermentation pathways that generate short-chain fatty acids such as butyrate. These microbial metabolites help regulate immune responses, support gut-barrier maintenance, and can influence host metabolic signaling (including pathways related to incretin activity and bile acid metabolism). Thoughtful carbohydrate quality choices—along with consistent meal patterns—may also help smooth post-meal glucose excursions while simultaneously feeding beneficial microbes.

    Adjunct lifestyle and clinical supports may further reinforce the gut–glycemia connection. Regular physical activity, adequate sleep, stress management, and minimizing unnecessary antibiotic exposure can help preserve microbial diversity and functional capacity. Some people may consider evidence-aligned probiotic or postbiotic options, particularly when GI symptoms or dysbiosis concerns are present, though strains and outcomes can vary. Overall, the goal of general support is to create a gut-friendly, low-inflammatory environment that improves nutrient handling, strengthens barrier function, and supports steadier metabolic and immune dynamics alongside optimized insulin therapy.

  • Lifestyle recommendations

    • Aim for a high-fiber, minimally processed diet (e.g., legumes, vegetables, whole grains, nuts, seeds) to support gut microbial diversity and gut-barrier integrity.
    • Use individualized, consistent carbohydrate distribution with attention to low-glycemic/slow-digesting carb sources to reduce glucose variability and support more stable gut-derived signaling.
    • Prioritize fermented foods if tolerated (e.g., yogurt/kefir, sauerkraut, kimchi) and consider discussing probiotics with a clinician to support a healthier microbiome balance.
    • Maintain regular physical activity (a mix of aerobic activity and resistance training) to improve insulin sensitivity and may positively influence microbiome function and inflammation.
    • Manage sleep and circadian rhythm (consistent sleep schedule, adequate duration) because disrupted circadian timing can impair glucose control and gut microbial communities.
    • Limit alcohol and avoid ultra-processed foods/sugary beverages as much as possible to reduce inflammation and dysbiosis that can worsen glycemic stability.
    • If you have gastrointestinal symptoms, seek tailored guidance (e.g., dietitian/clinician) and consider evaluating triggers (e.g., certain fibers/FODMAPs) rather than making abrupt, broad changes.

  • Nutrition recommendations

    • Prioritize high-fiber, plant-forward carbs (vegetables, legumes, whole grains, nuts/seeds) to support microbial diversity and increase beneficial fermentation of fiber into short-chain fatty acids (e.g., butyrate), which support gut-barrier integrity and may reduce inflammation-driven glycemic variability.
    • Choose predominantly low–glycemic impact carbohydrates and pair carbs with protein and healthy fats (e.g., beans + olive oil + lean protein) to blunt postprandial glucose spikes while helping maintain a more stable gut microbial metabolic environment.
    • Include regularly fermented foods (e.g., yogurt with live cultures, kefir, kimchi, sauerkraut, tempeh) to introduce beneficial microbes and metabolites; start with small portions if you have GI sensitivity.
    • Use a ‘prebiotic’ approach daily by adding foods rich in inulin/FOS and other prebiotic fibers (e.g., onions, garlic, leeks, asparagus, chicory root, bananas that are less ripe), aiming to feed commensal bacteria—ideally increasing gradually to avoid bloating.
    • Emphasize omega-3–rich foods (fatty fish like salmon/sardines, chia, ground flax, walnuts) while limiting ultra-processed foods and excess added sugars to reduce pro-inflammatory signals and support a gut community that favors metabolic stability.
    • Support gut barrier function with adequate micronutrients and polyphenols (berries, citrus, leafy greens, olive oil, cocoa, green tea) rather than relying on supplements alone; polyphenols can act as substrates for beneficial microbial metabolism.
    • Consider individualized carbohydrate “dose” and meal timing consistency (consistent meal composition and spacing when possible) to reduce gut-driven and insulin-driven oscillations; work with your diabetes clinician to align nutrition changes with insulin adjustments.

  • Supplement considerations

    For established type 1 diabetes (T1D), gut-targeted supplements are often considered to support insulin stability indirectly by improving intestinal barrier function, reducing low-grade inflammation, and promoting a healthier microbial ecosystem. Because people with established T1D frequently show altered microbial diversity and composition, interventions that encourage beneficial taxa and microbial metabolic activity (for example, via targeted prebiotic fibers or carefully selected probiotics) may help shift immune signaling away from a pro-inflammatory state that can worsen glucose variability and metabolic instability.

    Supplement choices may also focus on microbial metabolites that influence host glucose regulation. Short-chain fatty acids (notably butyrate) and other fermentation products can support gut barrier integrity and regulate immune pathways, potentially improving metabolic resilience. In practice, this often means considering supplements that provide fermentable substrates (prebiotics) or those designed to increase production of SCFAs, while also being mindful that individual carbohydrate fermentation capacity can vary—an important consideration for people managing glycemia closely. Bile acid–related metabolism is another gut link; some microbiome-directed approaches may indirectly affect bile acid signaling (e.g., through farnesoid X receptor/FXR and related pathways), which can influence glucose handling and incretin-related signaling.

    As with any adjunct strategy in T1D, safety and real-world tolerability matter. GI symptoms, changes in stool consistency, and individual responses to specific strains or fiber types can all affect adherence and glycemic patterns, so starting low and monitoring blood glucose trends is key. Those with recent infections, significant gastroparesis, or other complex GI conditions may need more conservative selection and clinician oversight. Finally, supplement use should complement—never replace—optimized insulin therapy and standard medical guidance, with the most evidence-aligned approach typically emphasizing personalized microbiome support (rather than broad, high-dose or indiscriminate use).

  • Retesting / monitoring note

    For people with established type 1 diabetes (T1D), retesting recommendations typically focus on reassessing factors that can shift gut microbiome–linked glycemic variability over time, rather than assuming the microbiome is static. Because diet pattern, fiber intake, gastrointestinal symptoms, recent infections, antibiotics, travel, and changes in medication can rapidly alter microbial diversity and metabolic output, re-evaluations are often considered after meaningful “reset” events such as antibiotic exposure, sustained dietary changes, or a period of worsening glucose stability. Retesting can also be appropriate if there are new or persistent GI symptoms (e.g., bloating, diarrhea, constipation) that may reflect changes in intestinal permeability and immune activation.

    In established T1D, gut-barrier health and low-grade inflammation are key mechanistic bridges between microbiome shifts and glucose control. Retesting may be recommended when there are signs of escalating inflammation-related disruption—such as rising inflammatory markers, increased frequency of unexplained glucose swings, or increased infection susceptibility—since microbial community changes (and their metabolites) can influence tight-junction integrity and immune signaling. Reassessment is especially useful if prior results suggested reduced microbial diversity or altered functional potential (e.g., changes in fermentation products), because those functional shifts may correlate with altered short-chain fatty acid (SCFA) production and bile acid signaling that affect metabolic stability.

    When retesting is considered, it’s important to standardize timing and pre-analytical conditions to make results interpretable. Many clinicians and research protocols aim to repeat testing when the person has been on a relatively consistent routine for a few weeks—before and after major interventions—so the signal reflects longer-term community/function rather than day-to-day variability. Intervals may vary based on clinical goals and prior findings, but commonly fall in the range of several months for ongoing monitoring, with earlier retesting after major perturbations (e.g., antibiotics or other large microbiome-disrupting exposures).

The importance of gut microbiome testing

  • Why testing matters

    In established type 1 diabetes (T1D), insulin deficiency is the core issue, but day-to-day glucose stability is also influenced by gut microbial ecology. Gut microbiome testing matters because many people with T1D show altered microbial diversity and community composition compared with those without the condition. Those differences can be associated with distinct microbial metabolic functions—such as how efficiently carbs are fermented and which metabolites are produced—that may affect circulating compounds involved in glycemic variability, inflammation tone, and food tolerance.

    A key reason testing can be actionable is the microbiome’s relationship with gut-barrier health and immune signaling. Certain microbial patterns can influence intestinal permeability and tight-junction integrity, potentially increasing the immune system’s exposure to pro-inflammatory triggers. For someone living with established T1D, chronic low-grade inflammation can worsen insulin sensitivity and contribute to persistent metabolic instability, even when insulin dosing is optimized—so identifying microbiome features linked to barrier dysfunction may help explain why glucose swings remain difficult to control.

    Microbiome testing is also valuable because it can reveal how gut-derived metabolites and signaling pathways may be impacting glucose regulation beyond inflammation. Microbes produce short-chain fatty acids (like butyrate), modulate bile acid metabolism, and generate fermentation products that interact with host receptors and pathways involved in nutrient handling and incretin-related hormone signaling. By connecting individual microbial signatures to potential metabolite and pathway profiles, microbiome testing can support more personalized dietary and therapeutic strategies aimed at improving glycemic stability, GI symptoms, and overall immune balance.

  • How InnerBuddies helps

    In established type 1 diabetes, insulin deficiency drives baseline glucose control, but day-to-day glycemic stability is also influenced by the gut microbiome. InnerBuddies helps by assessing gut microbial ecology, including diversity and community patterns that are often different in people with T1D compared with those without. These microbial shifts can correspond to changes in microbial metabolic capacity—such as fermentation efficiency and the types of bioactive metabolites produced—that may affect circulating compounds related to glucose variability, inflammation signaling, and how the body responds to meals.

    A particularly important pathway in established T1D is gut-barrier health and immune tone. Some gut microbial patterns can influence intestinal permeability and tight-junction integrity, which can increase immune exposure to inflammatory triggers. InnerBuddies can help identify microbiome features that may be associated with a more pro-inflammatory gut environment, offering a framework to understand why blood-sugar swings or metabolic instability can persist even when insulin therapy is optimized. This added context supports more targeted lifestyle and nutrition decisions intended to reduce inflammatory pressure and improve metabolic steadiness.

    InnerBuddies also helps by connecting microbial signals to potential host metabolic effects beyond inflammation. Gut microbes produce short-chain fatty acids (including butyrate), shape bile acid metabolism, and generate fermentation byproducts that interact with host receptors and nutrient-handling pathways linked to incretin signaling and glucose regulation. By clarifying the gut signatures most likely to reflect these functional effects, InnerBuddies can guide more personalized dietary strategies aimed at improving GI tolerance, supporting gut-derived metabolic signaling, and potentially reducing fluctuations in hyperglycemia/hypoglycemia over time.

Medical Evidence

  • Scientific evidence level

    2 [weak (emerging but inconsistent)]

  • Clinical relevance note

    Current clinical relevance is limited. While several studies report statistically significant microbiome differences between people with established T1D and controls, these findings are not consistently reproducible across studies and are highly sensitive to confounding (diet, medications, sampling/processing, antibiotics, disease duration). Consequently, there is no validated gut microbiome test that clinicians can use for routine diagnosis confirmation, complication risk stratification, or monitoring therapeutic response in established T1D.

    Actionable intervention relevance is also not established. Microbiome-targeted interventions in established T1D have not yet demonstrated consistent, clinically meaningful improvements in outcomes that matter to patients and clinicians (e.g., sustained improvement in glycemic control with durable benefit, reduced insulin dose needs, or reduced complication incidence). Methodological limitations (small sample sizes, heterogeneous intervention regimens, variable endpoints, batch effects, lack of external validation) prevent strong recommendations. In short: the gut microbiome remains a promising research domain for understanding and potentially modulating autoimmunity-related pathways, but present evidence does not justify routine clinical implementation for established T1D beyond research settings.

Title Journal Year Link
Gut microbiome in type 1 diabetes: a systematic review and meta-analysis Gut Microbes 2020 View →
Gut microbiota and autoimmunity: new insights and therapeutic opportunities Nature Reviews Immunology 2017 View →
Gut microbiota in early life and the risk of type 1 diabetes Diabetes 2016 View →
Distinct gut microbiomes are associated with early-onset type 1 diabetes Diabetologia 2015 View →
Transfer of microbial consortia from nonobese diabetic mice to germ-free mice drives diabetes Cell Host & Microbe 2014 View →

Frequently Asked Questions

    ¿Qué es el microbioma intestinal y por qué importa en el T1D establecido?
    El microbioma intestinal es la comunidad de microbios en el intestino. En el T1D establecido, las diferencias en su composición y actividad metabólica pueden estar relacionadas con la inflamación y la variabilidad glucémica diaria. La evidencia avanza; no es un sustituto de las terapias estándar para la diabetes.
    ¿Cómo podría la disbiosis intestinal afectar el control de la glucosa en el T1D establecido?
    La disbiosis podría alterar la barrera intestinal, las señales inmunitarias y los metabolitos microbianos que influyen en la regulación de la glucosa y la sensibilidad a la insulina. Los hallazgos son preliminares.
    ¿Qué síntomas podrían indicar problemas relacionados con el microbioma en el T1D establecido?
    Síntomas GI como hinchazón, diarrea o estreñimiento y fluctuaciones más marcadas de la glucosa; la sed y la diuresis son comunes en el T1D pero no son específicas del microbioma. Consulte a un médico ante nuevos síntomas.
    ¿Existen grupos bacterianos específicos vinculados a una mejor o peor regulación de la glucosa?
    Algunos estudios asocian patrones de menor diversidad o cambios en ciertos grupos, pero las relaciones son complejas y no probadas como causalidad. No es una herramienta diagnóstica.
    ¿Se recomienda hacer pruebas del microbioma en personas con T1D establecido?
    Las pruebas pueden aportar información sobre la ecología intestinal, pero no son una práctica estándar y deben discutirse con un médico. No sustituyen la insulinoterapia.
    ¿Cambiar la dieta o tomar probióticos/prebióticos puede mejorar la estabilidad glucémica?
    La calidad de la dieta y algunos enfoques probióticos/prebióticos están en estudio. Los efectos varían; hable con un profesional de la salud para un plan personalizado.
    ¿Los cambios en el microbioma pueden reemplazar la terapia con insulina?
    No. La insulinoterapia sigue siendo esencial. Los cambios del microbioma pueden influir en la variabilidad, pero no reemplazan la insulinoterapia.
    ¿Cómo podrían los metabolitos derivados del microbioma influir en la regulación de la glucosa?
    Los microbios producen ácidos grasos de cadena corta (como el butirato) y modifican ácidos biliares, lo que puede afectar hormonas como GLP-1 y la producción hepática de glucosa.
    ¿Cuál es el papel de la integridad de la barrera intestinal en el T1D?
    Una mayor permeabilidad intestinal puede aumentar la exposición a señales inflamatorias y favorecer la resistencia a la insulina. Es un tema de investigación.
    ¿Los antibióticos u otros medicamentos pueden afectar al microbioma intestinal?
    Sí. Algunos fármacos pueden alterar los microbios y sus metabolitos. Consúltelo con su médico.
    ¿Qué ofrece InnerBuddies respecto al microbioma en el T1D establecido?
    Ofrece un marco para entender patrones microbianos y sus posibles implicaciones metabólicas para apoyar decisiones dietéticas y de estilo de vida personalizadas, dentro de la atención estándar; no es un tratamiento.
    ¿Qué preguntas debo hacer a mi médico sobre las pruebas del microbioma?
    Pregunte sobre los objetivos de la prueba, qué mide, cómo podrían influir los resultados en la atención, costos y cómo interpretar los resultados dentro del manejo del T1D.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -